The humanin peptide occupies a unique position in biomedical research as the first identified mitochondrial-derived peptide (MDP) with demonstrated cytoprotective activity. Discovered in 2001 through a functional screen for factors that protect neurons from Alzheimer’s disease-related toxicity, humanin has since been implicated in neuroprotection, metabolic regulation, cellular stress resistance, and aging biology.

This research guide examines humanin’s mitochondrial origins, its multi-receptor signaling mechanism, key findings in neuroprotection and metabolic research, the relationship to related mitochondrial peptides like MOTS-c, and current directions in longevity science.

What Is Humanin and How Was This Mitochondrial Peptide Discovered?

Humanin is a 24-amino-acid peptide encoded by the 16S ribosomal RNA region of the mitochondrial genome (mtDNA). Its discovery by Hashimoto and colleagues in 2001 was unexpected: the research team was screening a cDNA expression library from the occipital cortex of an Alzheimer’s disease patient for factors that could rescue cells from amyloid-beta induced death. The protective clone they identified mapped not to the nuclear genome but to the mitochondrial genome, an organellar DNA previously thought to encode only 13 structural proteins of the electron transport chain, plus tRNAs and rRNAs (Hashimoto et al., 2001, Proc Natl Acad Sci USA).

This discovery established a new paradigm: mitochondria can encode bioactive peptides beyond the canonical oxidative phosphorylation components. The subsequent identification of additional mitochondrial-derived peptides, including MOTS-c, SHLP1 through SHLP6, and others, confirmed that the mitochondrial genome contains a previously unrecognized peptidome with broad biological activity.

The humanin sequence (MAPRGFSCLLLLTSEIDLPVKRRA) is remarkably conserved across species, showing near-identical sequences in organisms as divergent as humans, rodents, and nematodes. This evolutionary conservation strongly suggests essential biological function maintained by natural selection over hundreds of millions of years.

How Does Humanin Peptide Signal in Cells?

Humanin exerts its biological effects through multiple receptor-mediated and intracellular mechanisms, reflecting the complexity expected of a highly conserved cytoprotective factor.

The CNTFR/WSX-1/gp130 Trimeric Receptor

Humanin’s primary identified receptor complex consists of three components: ciliary neurotrophic factor receptor alpha (CNTFR), interleukin-27 receptor subunit WSX-1, and glycoprotein 130 (gp130). This trimeric complex was identified through receptor pulldown and functional studies showing that humanin activates JAK-STAT3 signaling through this receptor assembly (Hashimoto et al., 2009, Mol Biol Cell).

JAK-STAT3 activation by humanin triggers transcription of anti-apoptotic genes including Bcl-2 family members and survival factors. This signaling cascade provides a direct molecular mechanism for humanin’s observed cytoprotective effects across multiple cell types and stress conditions.

FPRL1/FPRL2 Receptor Binding

Humanin also binds formyl peptide receptor-like 1 and 2 (FPRL1/FPRL2), receptors involved in innate immunity and inflammation resolution. Activation of these receptors by humanin suppresses inflammatory signaling cascades and promotes the resolution of inflammation, contributing to humanin’s protective effects in neuroinflammatory and metabolic disease models.

Intracellular Interactions: IGFBP-3 and Bax

Beyond surface receptor signaling, humanin directly interacts with intracellular proteins. Humanin binds insulin-like growth factor binding protein-3 (IGFBP-3), neutralizing IGFBP-3’s pro-apoptotic activity. It also directly binds the pro-apoptotic protein Bax, preventing Bax translocation to the mitochondrial membrane and blocking the intrinsic apoptosis pathway.

This multi-level signaling architecture, engaging surface receptors, intracellular binding partners, and transcriptional programs simultaneously, likely explains why humanin provides robust cytoprotection across diverse stress conditions and cell types.

Humanin Neuroprotection Research

The neuroprotective properties of humanin represent the most extensively studied aspect of this peptide’s biology, rooted in its original discovery context of Alzheimer’s disease research.

Alzheimer’s Disease Models

In cell culture models, humanin protects neurons from toxicity induced by multiple Alzheimer’s-relevant insults: amyloid-beta 1-42 aggregates, amyloid-beta 1-43 peptides, and the intracellular domain of amyloid precursor protein (APP). The protection is dose-dependent, with humanin analogs showing efficacy at nanomolar concentrations.

In transgenic mouse models of Alzheimer’s disease, systemically administered humanin analogs (particularly the potent analog [Gly14]-Humanin, or HNG) reduced amyloid plaque burden, improved spatial memory performance in Morris water maze testing, and decreased neuroinflammatory markers. These in vivo results demonstrated that humanin can cross the blood-brain barrier at functionally relevant concentrations.

Broader Neuroprotective Applications

Beyond Alzheimer’s disease, humanin neuroprotection research has expanded to include stroke, traumatic brain injury, and other neurodegenerative conditions. In rodent stroke models, humanin treatment reduced infarct volume when administered within hours of ischemic onset. In prion disease models, humanin delayed symptom onset and extended survival.

The mechanistic basis for this broad neuroprotection appears to involve humanin’s ability to preserve mitochondrial function under stress. By preventing Bax-mediated mitochondrial membrane permeabilization and maintaining electron transport chain integrity, humanin supports cellular energy production during conditions that would otherwise trigger mitochondrial-dependent apoptosis.

Age-related macular degeneration (AMD) research has also incorporated humanin, given the retina’s exceptionally high mitochondrial density and susceptibility to oxidative damage. In retinal pigment epithelial cell models, humanin protected against oxidative stress-induced cell death at nanomolar concentrations, suggesting potential relevance to the most common cause of age-related blindness. These findings further illustrate the breadth of humanin’s cytoprotective capacity across diverse tissue types.

Peripheral neuropathy models represent yet another neuroprotective application. Humanin treatment reduced nerve fiber degeneration and preserved nerve conduction velocity in diabetic neuropathy animal models, indicating protective effects on peripheral as well as central nervous system neurons. This broad neuronal protection across both central and peripheral compartments distinguishes humanin from neuroprotective compounds with more limited tissue specificity.

Researchers interested in the intersection of mitochondrial function and neurological health can find related compound analyses in our SS-31 (elamipretide) guide and our SS-31 vs MOTS-c mitochondrial comparison.

Metabolic Effects of Humanin

Emerging research has revealed that humanin plays significant roles in metabolic regulation beyond its neuroprotective functions. Circulating humanin levels correlate with metabolic health parameters, and exogenous humanin administration produces measurable metabolic effects in preclinical models.

Insulin Sensitivity and Glucose Metabolism

Humanin improves insulin sensitivity in both lean and obese animal models. In high-fat diet-fed mice, humanin treatment reduced fasting glucose levels, improved glucose tolerance test results, and decreased hepatic glucose output. These effects appear to be mediated in part through humanin’s interaction with IGFBP-3, which modulates IGF-1 bioavailability and insulin signaling cross-talk.

Epidemiological studies in human populations have found that circulating humanin levels decline with age and are lower in individuals with type 2 diabetes compared to age-matched controls. Higher humanin levels correlate with better insulin sensitivity and lower inflammatory marker concentrations, suggesting humanin may serve as both a biomarker and a functional mediator of metabolic health.

Lipid Metabolism

Humanin treatment in animal models has demonstrated effects on lipid metabolism including reduced visceral adiposity, decreased circulating triglycerides, and improved hepatic lipid handling. These effects may be downstream consequences of improved insulin sensitivity or may reflect direct humanin signaling in adipocytes and hepatocytes, where the trimeric receptor complex is expressed.

Humanin and Aging Research: The Longevity Connection

The relationship between humanin longevity research and aging biology represents one of the most compelling areas of current investigation. Multiple lines of evidence connect humanin to the aging process.

Age-Related Decline in Humanin Levels

Circulating humanin levels decline progressively with age across multiple species studied. In humans, plasma humanin concentrations are approximately 40 to 60% lower in adults over 70 compared to young adults. In mice, the decline parallels age-related increases in oxidative stress markers and decreases in mitochondrial function.

A particularly intriguing finding is that children of centenarians (a population enriched for longevity-associated genetics) have higher circulating humanin levels than age-matched controls whose parents did not achieve exceptional longevity. This suggests that maintained humanin production may be a heritable trait associated with extended healthspan (PubMed: humanin and exceptional longevity).

Growth Hormone/IGF-1 Axis Intersection

A fascinating connection exists between humanin and the GH/IGF-1 signaling axis that governs much of mammalian aging biology. Growth hormone receptor knockout mice, which are among the longest-lived laboratory mouse models, have significantly elevated circulating humanin levels. Similarly, caloric restriction, the most robust longevity intervention in animal models, increases humanin expression.

These observations suggest that humanin may be part of the protective signaling network activated when growth-promoting pathways are suppressed, a condition consistently associated with extended lifespan across species. For researchers studying the broader landscape of longevity compounds, our best peptides for longevity and anti-aging guide covers the full spectrum of relevant compounds.

Humanin and MOTS-c: Related Mitochondrial Peptides

Humanin’s discovery catalyzed the identification of additional humanin mitochondrial peptide family members, most notably MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c). While both are encoded by the mitochondrial genome, their mechanisms and primary research applications differ in important ways.

MOTS-c is a 16-amino-acid peptide encoded by the 12S rRNA region of mtDNA. Its primary mechanism involves activation of AMPK (AMP-activated protein kinase), the cellular energy sensor, producing effects on glucose metabolism, exercise physiology, and metabolic homeostasis. While humanin’s strengths lie in neuroprotection and anti-apoptotic activity, MOTS-c’s primary research focus has been metabolic regulation and exercise biology.

The two peptides share the common feature of mitochondrial origin and age-related decline, suggesting they may function as coordinated components of a mitochondrial signaling system that deteriorates with aging. Combined research protocols examining both peptides simultaneously are becoming increasingly common in aging and metabolic studies.

MOTS-c is available as a research compound. Our MOTS-c peptide metabolic health guide provides comprehensive coverage of its mechanism and research applications.

Humanin in Cardiovascular Research

Beyond neuroprotection and metabolism, humanin research has extended into cardiovascular biology with promising preclinical results. Humanin treatment reduced atherosclerotic plaque formation in ApoE-knockout mice, a standard model for cardiovascular disease. The mechanism involved suppression of macrophage-derived foam cell formation and reduction of oxidized LDL uptake in arterial walls.

In cardiac ischemia-reperfusion models, humanin administration before reperfusion reduced myocardial infarct size by 30 to 40%. This cardioprotection was mediated through mitochondrial preservation, with humanin preventing the opening of the mitochondrial permeability transition pore (mPTP) that triggers cardiomyocyte death during reperfusion injury.

Endothelial function studies have shown that humanin improves nitric oxide bioavailability and reduces endothelial senescence markers in aged vascular tissue. These vascular effects may contribute to the association between higher circulating humanin levels and reduced cardiovascular mortality observed in epidemiological studies.

The convergence of humanin’s anti-apoptotic, anti-inflammatory, and mitochondria-protective activities makes it particularly relevant to cardiovascular aging research, where mitochondrial dysfunction in cardiomyocytes and vascular endothelium drives progressive functional decline.

Humanin Analogs and Research Tools

Several humanin analogs have been developed to enhance potency, stability, or receptor selectivity for research applications.

[Gly14]-Humanin (HNG) is the most widely used potent analog, containing a single amino acid substitution (Ser14 to Gly) that increases cytoprotective potency by approximately 1,000-fold compared to native humanin. HNG has become the standard research tool for in vivo studies where higher potency reduces the amount of peptide required and improves dose-response characterization.

S7 humanin, a shorter 7-amino-acid fragment derived from the C-terminal region, retains partial activity and has been used to map the minimum active domain. Colivelin, a hybrid peptide incorporating the humanin active domain fused to a cell-penetrating sequence, demonstrates enhanced blood-brain barrier penetration for neuroscience applications.

Rationally designed analogs with enhanced stability have been developed by incorporating D-amino acid substitutions at protease-susceptible sites while maintaining receptor binding activity. These stabilized variants demonstrate extended circulating half-lives in vivo, enabling less frequent dosing in chronic administration studies and improving bioavailability for systemic delivery.

Structure-activity relationship studies have mapped the critical residues for cytoprotective activity to positions 3, 7, 14, and 17 through 24 of the humanin sequence. Modifications at position 14 (the Ser to Gly substitution in HNG) and position 8 produce the most dramatic changes in potency, providing guidance for researchers designing custom analogs for specific experimental applications.

For researchers building comprehensive longevity research programs, humanin analogs are often studied alongside other longevity-associated compounds including epitalon, which targets telomere biology through a different mechanism.

Where to Buy Related Mitochondrial Research Peptides

Researchers investigating mitochondrial-derived peptides and longevity biology can access the related compound MOTS-c, humanin’s mitochondrial peptide counterpart, from PSPeptides. MOTS-c provides a complementary tool for studying the mitochondrial peptidome’s role in metabolic regulation and aging.

PSPeptides supports longevity and mitochondrial research with quality assurances that matter for reproducible results:

• Certificate of Analysis (COA) documenting HPLC purity, mass spectrometry identity confirmation, and endotoxin testing for every batch
• Same-day shipping on qualifying orders with appropriate packaging for peptide stability
• Afterpay and Klarna payment flexibility for research budgets of any size
• Research supplies bundling with bacteriostatic water, syringes, and reconstitution accessories available alongside peptide orders

Third-party analytical verification ensures that researchers receive compounds matching published specifications, enabling confident comparison with literature data.

Frequently Asked Questions About Humanin

What makes humanin different from other research peptides?

Humanin is unique because it is encoded by the mitochondrial genome rather than nuclear DNA. This mitochondrial origin means humanin levels are directly tied to mitochondrial copy number, function, and integrity. As mitochondrial function declines with aging, humanin production decreases correspondingly, creating a direct molecular link between mitochondrial health and the cytoprotective signaling humanin provides.

How does humanin provide neuroprotection?

Humanin provides neuroprotection through multiple parallel mechanisms. It activates the JAK-STAT3 survival pathway through its trimeric receptor complex (CNTFR/WSX-1/gp130). It directly binds and neutralizes the pro-apoptotic protein Bax, preventing mitochondrial membrane permeabilization. And it sequesters IGFBP-3, blocking its pro-apoptotic signaling. This multi-level protection explains humanin’s broad-spectrum neuroprotective efficacy across diverse stress conditions.

What is the relationship between humanin and MOTS-c?

Both humanin and MOTS-c are mitochondrial-derived peptides encoded by the mitochondrial genome, but they have distinct mechanisms and primary research applications. Humanin is encoded by the 16S rRNA gene region and acts primarily through cytoprotective and anti-apoptotic pathways. MOTS-c is encoded by the 12S rRNA region and acts primarily through AMPK activation to regulate metabolic function. Both decline with age, suggesting coordinated mitochondrial signaling in aging biology.

All PSPeptides products are sold exclusively for research and laboratory use.